Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer	Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Recruiting	Phase 1	2026-09-25		NCT06801236

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Acerand Therapeutics (Hong Kong) Limited	1

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Gobroard Hospital	Beijing	China	1
Carolina Urologic Research Center	Myrtle Beach	United States	55
Fred Hutchinson Cancer Research Center	Seattle	United States	71
Fujian Cancer Hospital	Fuzhou	China	55
Harvard Medical School-Massachusetts General Hospital	Boston	United States	1
Henan Cancer Hospital	Zhengzhou	China	1
M Health Fairview Clinics and Surgery Center	Minneapolis	United States	6
Moffitt Cancer Center, Tampa	Tampa	United States	1
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	China	1
University of California San Diego, Moores Cancer Center	La Jolla	United States	1
University of Maryland, Greenebaum Comprehensive Cancer Center	Baltimore	United States	3
Xcancer (Urology Cancer Center)	Omaha	United States	1
Zhejiang Cancer Hospital	Hangzhou	China	1